Marksans Pharma Ltd stocks rose over 2% in intraday trade on Thursday, May 15, after a significant regulatory success. Its UK subsidiary company Relonchem Ltd, has received marketing authorisation from the UK Medicines and Healthcare products Regulatory Agency (UKMHRA) for Gabapentin oral solution (50 mg/ml), a commonly prescribed drug for pain caused by malfunctioning nerves and epilepsy. The oral liquid preparation is especially beneficial for patients suffering from swallowing difficulties with the usual tablets or capsules.

The news increased the optimism among investors, and the share of Marksans Pharma reached an intraday high of ₹243.65, higher by 2.3%. The stock was in the positive territory at 2:50 PM at ₹240.61, higher by almost 1% from the last close.

Why the Approval Matters

Marksans Pharma Gabapentin UK approval is an important addition to the firm's global portfolio of central nervous system (CNS) medicines. Gabapentin is an important CNS drug for the treatment of long-term nerve conditions and is prescribed in substantial quantities in Europe and North America. The oral solution that has recently been approved in the UK simplifies treatment—particularly for elderly patients, pediatric patients, and those who have swallowing problems.

“This clearance further strengthens our CNS product offerings in the UK and reaffirms our commitment to providing high-quality, patient-centric solutions," stated Harshavardhan Panigrahi, Marksans Pharma Company Secretary.

By targeting underserved patient groups and focusing on different dosage forms, Marksans Pharma is aggressively shifting towards expanding its therapeutic footprint globally.

Global Regulatory Momentum

Marksans Pharma Gabapentin UK approval follows a series of positive regulatory milestones for the company over the last few weeks. Marksans Pharma was approved in March by the Therapeutic Goods Administration (TGA) in Australia for the Verna, Goa plant. TGA approval will allow the plant to produce solid oral dosage forms—tablets and capsules—to serve the Australian market.

The same month, UKMHRA also approved Relonchem Ltd's Baclofen 10 mg tablets, a muscle relaxant for the treatment of symptoms of spinal cord injury and multiple sclerosis. The back-to-back approvals reflect Marksans Pharma's growing credibility and reliability in meeting highly stringent regulatory standards of developed economies like the UK and Australia.

Market Response and Outlook

The news was greeted well by investors, and Marksans Pharma was among the leading pharma stocks on May 15. While other stocks such as Kaya (+20%), Banco Products (+20%), and Premier Explosives (+18.31%) also caught the momentum, Marksans' rise was rooted in good fundamental news.

Marksans Pharma Gabapentin UK approval further solidifies its UK market platform and positions it in the broader European CNS pharmaceutical market, a multi-billion dollar opportunity. With regulatory platforms in the UK, Australia, and other developed markets, the company is well-positioned to continue its international expansion.

Final Takeaway 

Marksans Pharma Gabapentin UK approval is a strategic achievement that demonstrates the firm's capability to offer quality, cost-effective medication tailored to patient needs.

With an expanding CNS portfolio and increasing regulatory success in international markets, Marksans Pharma is positioning itself as a patient-focused, world-compliant pharma firm.

For those interested in exposure to growth pharma companies with international growth opportunities and compliance with regulations, Marksans Pharma is worth considering.